var data={"title":"Clinical manifestations and diagnosis of familial adenomatous polyposis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical manifestations and diagnosis of familial adenomatous polyposis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/contributors\" class=\"contributor contributor_credentials\">Daniel C Chung, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/contributors\" class=\"contributor contributor_credentials\">Tomer Adar, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/contributors\" class=\"contributor contributor_credentials\">Paul Rutgeerts, MD, PhD, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 28, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H11752496\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Familial adenomatous polyposis (FAP) is characterized by the presence of multiple colorectal adenomatous polyps (typically more than 100). Multiple colorectal adenomas may also be seen in individuals with <em>MUTYH-</em>associated polyposis (MAP). Other rare causes include the polymerase proofreading-associated polyposis (PPAP) syndrome or hereditary mixed polyposis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/1\" class=\"abstract_t\">1</a>].</p><p>This topic will review the genetics, clinical manifestations, and diagnosis of FAP. Surveillance strategies for FAP and the clinical features and diagnosis of <em>MUTYH</em>-associated polyposis and the hamartomatous polyposis syndromes are discussed separately. (See <a href=\"topic.htm?path=familial-adenomatous-polyposis-screening-and-management-of-patients-and-families\" class=\"medical medical_review\">&quot;Familial adenomatous polyposis: Screening and management of patients and families&quot;</a> and <a href=\"topic.htm?path=mutyh-associated-polyposis\" class=\"medical medical_review\">&quot;MUTYH-associated polyposis&quot;</a> and <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=juvenile-polyposis-syndrome\" class=\"medical medical_review\">&quot;Juvenile polyposis syndrome&quot;</a> and <a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome\" class=\"medical medical_review\">&quot;PTEN hamartoma tumor syndrome, including Cowden syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11752503\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Familial adenomatous polyposis (FAP) has an estimated prevalence of three cases per 100,000 individuals and accounts for less than 1 percent of all colorectal cancers in the United States [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/2\" class=\"abstract_t\">2</a>]. It affects both sexes equally and has a worldwide distribution [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H547090028\"><span class=\"h1\">GENETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Familial adenomatous polyposis (FAP) and its variants are caused by germline mutations in the tumor suppressor gene, <em>Adenomatous Polyposis Coli</em> (<em>APC</em>), located on chromosome 5q21-q22 [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/4\" class=\"abstract_t\">4</a>].</p><p>FAP follows an autosomal dominant pattern of inheritance with nearly complete penetrance of colonic polyposis but variable penetrance of the extracolonic manifestations of the disease. Up to 25 percent of FAP cases are due to new or <em>de novo APC </em>mutations [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/5\" class=\"abstract_t\">5</a>]. Such patients do not have a family history of FAP. (See <a href=\"topic.htm?path=genetics-glossary-of-terms\" class=\"medical medical_review\">&quot;Genetics: Glossary of terms&quot;</a> and <a href=\"topic.htm?path=inheritance-patterns-of-monogenic-disorders-mendelian-and-non-mendelian\" class=\"medical medical_review\">&quot;Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)&quot;</a> and <a href=\"#H11752517\" class=\"local\">'Clinical manifestations'</a> below and <a href=\"topic.htm?path=inheritance-patterns-of-monogenic-disorders-mendelian-and-non-mendelian#H1957209762\" class=\"medical medical_review\">&quot;Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)&quot;, section on 'Incomplete or variable penetrance'</a>.)</p><p>More than 1000 different mutations of the <em>APC</em> gene associated with FAP have been described, most of which lead to frame shifts and premature stop codons [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/6,7\" class=\"abstract_t\">6,7</a>]. However, large deletions may account for up to 15 percent of cases [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/8-10\" class=\"abstract_t\">8-10</a>].</p><p>Inactivating mutations of both <em>APC </em>alleles are thought to be necessary for the development of adenomas in FAP [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/11\" class=\"abstract_t\">11</a>]. This typically results from an inherited mutation of one <em>APC</em> allele and a somatic mutation or deletion of the other allele [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/12\" class=\"abstract_t\">12</a>]. Mutations of both alleles in a single cell result in the absence of functional APC protein and aberrant accumulation of beta-catenin, leading to transcriptional activation of the <em>Wnt</em> (Wingless-type) signalling pathway and its target genes that control cell growth. (See <a href=\"topic.htm?path=molecular-genetics-of-colorectal-cancer#H13\" class=\"medical medical_review\">&quot;Molecular genetics of colorectal cancer&quot;, section on 'APC gene'</a>.)</p><p>Mutations of the <em>APC</em> gene also play a role in the development of sporadic colorectal cancer. Somatic <em>APC</em> mutations are found in as many as 80 percent of sporadic colorectal adenomas and cancers. (See <a href=\"topic.htm?path=molecular-genetics-of-colorectal-cancer\" class=\"medical medical_review\">&quot;Molecular genetics of colorectal cancer&quot;</a>.)</p><p>The location of the mutation within the <em>APC </em>gene has been associated with the severity of colonic polyposis, the degree of cancer risk, the age of cancer onset, survival, and the presence and frequency of extracolonic manifestations [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/13,14\" class=\"abstract_t\">13,14</a>]. As a general rule, mutations between codons 169 to 1393 are associated with classic FAP (see <a href=\"#H534324030\" class=\"local\">'Classic FAP'</a> below). Attenuated FAP (AFAP) is associated with mutations that are typically in the 5' (5' to codon 158) and 3' (3' to codon 1596) ends of the <em>APC</em> gene (see <a href=\"#H103627351\" class=\"local\">'Attenuated FAP'</a> below).</p><p>Several other genotype-phenotype correlations have also been reported, although there is considerable variability within families and among individuals with identical mutations [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/15\" class=\"abstract_t\">15</a>]. Mutations between codons 463 to 1444 have been associated with retinal lesions (congenital hypertrophy of the retinal pigment epithelium [CHRPE]) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/16-19\" class=\"abstract_t\">16-19</a>], mutations between codons 1445 and 1578 have been associated with desmoid tumors [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/18-20\" class=\"abstract_t\">18-20</a>], mutations between codons 279 to 1309 have been associated with duodenal polyposis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/21\" class=\"abstract_t\">21</a>], and mutations between codons 686 and 1217 have been associated with medulloblastoma [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/22\" class=\"abstract_t\">22</a>]. (See <a href=\"topic.htm?path=genetics-glossary-of-terms\" class=\"medical medical_review\">&quot;Genetics: Glossary of terms&quot;</a> and <a href=\"#H11752517\" class=\"local\">'Clinical manifestations'</a> below.)</p><p class=\"headingAnchor\" id=\"H11752517\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Familial adenomatous polyposis (FAP) is characterized by the presence of numerous colorectal adenomas (usually hundreds). A number of extracolonic manifestations have also been associated with FAP.</p><p>The majority of patients are asymptomatic until they present with symptoms of colorectal cancer. In such cases, patients with FAP may present with gastrointestinal bleeding, abdominal pain, and diarrhea. Most patients are diagnosed between 20 to 40 years of age, and 75 percent of them are symptomatic. These rates may change with increased awareness and availability of genetic testing [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/23\" class=\"abstract_t\">23</a>]. (See <a href=\"topic.htm?path=clinical-presentation-diagnosis-and-staging-of-colorectal-cancer#H2\" class=\"medical medical_review\">&quot;Clinical presentation, diagnosis, and staging of colorectal cancer&quot;, section on 'Clinical presentation'</a>.)</p><p class=\"headingAnchor\" id=\"H534324675\"><span class=\"h2\">Colonic manifestations</span></p><p class=\"headingAnchor\" id=\"H534324030\"><span class=\"h3\">Classic FAP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Classic FAP is characterized by the presence of 100&rsquo;s to 1000&rsquo;s of adenomatous colorectal polyps (<a href=\"image.htm?imageKey=GAST%2F59413\" class=\"graphic graphic_picture graphicRef59413 \">picture 1</a> and <a href=\"image.htm?imageKey=GAST%2F73267\" class=\"graphic graphic_picture graphicRef73267 \">picture 2</a>). Patients with profuse polyposis often exhibit an earlier age of onset. Mutations located between codons 1250 to 1464 [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/24\" class=\"abstract_t\">24</a>].</p><p>Diffuse polyposis typically develops in the second or third decade of life. The mean age of polyp emergence is 16 years, but the onset of polyps has been noted in patients as young as eight years [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/25\" class=\"abstract_t\">25</a>].</p><p>Colorectal cancer occurs in nearly 100 percent of individuals with FAP if untreated, with an average age of 39 years at cancer diagnosis. Approximately 40 percent of individuals with colorectal cancer have synchronous malignancies, and over 80 percent of tumors are left sided [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/26,27\" class=\"abstract_t\">26,27</a>]. Adenomas in patients with FAP behave in a similar manner to sporadic adenomas and do not intrinsically have a higher malignant potential. The increased risk of colorectal cancer in FAP is attributable to the vast number of adenomas that occur at an early age (<a href=\"image.htm?imageKey=GAST%2F58291\" class=\"graphic graphic_figure graphicRef58291 \">figure 1</a>); over time, one or more of these adenomas invariably progresses to colorectal cancer.</p><p class=\"headingAnchor\" id=\"H103627351\"><span class=\"h3\">Attenuated FAP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A milder or attenuated form of FAP has been recognized [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/28-32\" class=\"abstract_t\">28-32</a>]. Although there is no consensus regarding the precise definition of attenuated FAP (AFAP), it is typically characterized by oligopolyposis (10 to 99 adenomas). Adenomas and cancer in AFAP are diagnosed at a later age than in classic FAP (mean ages of 44 and 58 years, respectively) and are characterized by a more proximal distribution in the colon [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/30,33\" class=\"abstract_t\">30,33</a>]. The overall risk of colorectal cancer in AFAP remains high, but is somewhat lower (~80%) compared to classic FAP. </p><p class=\"headingAnchor\" id=\"H534324165\"><span class=\"h2\">Extracolonic manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polyps occur in the upper gastrointestinal tract in 30 to 100 percent of patients with FAP [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/34,35\" class=\"abstract_t\">34,35</a>].</p><p>Fundic gland polyps are found in most patients with FAP. These are small (&lt;1 cm), sessile polyps located in the fundus or body of the stomach, and some patients may have hundreds of these lesions [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/36\" class=\"abstract_t\">36</a>]. Fundic gland polyps are composed of normal gastric corpus-type epithelium arranged in a disorderly <span class=\"nowrap\">and/or</span> microcystic configuration. Low-grade dysplasia occurs in nearly half of fundic gland polyps, although they rarely progress to cancer [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/37\" class=\"abstract_t\">37</a>]. Gastric adenomas are much less common than fundic gland polyps in patients with FAP; they are typically isolated, located in the antrum, and are associated with a relatively low but definite risk of progression to cancer. (See <a href=\"topic.htm?path=gastric-polyps#H9\" class=\"medical medical_review\">&quot;Gastric polyps&quot;, section on 'Fundic gland polyps'</a>.)</p><p>Duodenal adenomas occur in 45 to 90 percent of patients with FAP, and there is a predilection for the ampullary and periampullary regions. The lifetime risk for duodenal cancer is 5 percent, constituting the second most common cause of death in FAP patients [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/24,34,35\" class=\"abstract_t\">24,34,35</a>]. Adenomas can occur rarely in the gallbladder, bile duct, and the small bowel, particularly the distal ileum [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/34,38-40\" class=\"abstract_t\">34,38-40</a>].</p><p>Desmoid tumors are mesenchymal tumors that occur in 10 to 15 percent of FAP patients. Although these tumors are slow growing and do not metastasize, they may nevertheless cause significant morbidity and mortality. Desmoids are most commonly located in the abdomen, and while some may resolve spontaneously or remain stable, about 10 percent of cases will have a rapidly progressive course, compressing and encasing adjacent structures. This may result in pain, bowel obstruction, ureteral obstruction, and vascular compromise [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/41\" class=\"abstract_t\">41</a>]. </p><p>Approximately 80 percent of FAP patients have a nodular thyroid, and as many as 12 percent develop thyroid cancer, at a mean age of 28 years (range 12 to 62 years). Thyroid cancer is more common in women and is typically the papillary subtype and can be multifocal. The cribriform-morular variant accounts for about one-third of cases [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/42-44\" class=\"abstract_t\">42-44</a>]. (See <a href=\"topic.htm?path=papillary-thyroid-cancer\" class=\"medical medical_review\">&quot;Papillary thyroid cancer&quot;</a>.)</p><p>Hepatoblastomas are embryonal tumors that diagnosed at a mean age of 6 to 36 months and occur in 1.6 percent of FAP patients. Unlike desmoid and thyroid tumors, hepatoblastoma has a male predilection [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/26\" class=\"abstract_t\">26</a>]. </p><p>Approximately 1 to 2 percent of FAP patients develop brain tumors. These include medulloblastoma (80 percent of cases), ependymomas and high-grade astrocytoma, and this combination has been historically designated Turcot syndrome (see discussion below) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/45\" class=\"abstract_t\">45</a>]. (See <a href=\"#H534324100\" class=\"local\">'Gardner syndrome'</a> below and <a href=\"topic.htm?path=clinical-presentation-diagnosis-and-risk-stratification-of-medulloblastoma\" class=\"medical medical_review\">&quot;Clinical presentation, diagnosis, and risk stratification of medulloblastoma&quot;</a>.)</p><p>Sebaceous or epidermoid cysts, lipomas, osteomas, fibromas, supernumerary teeth, juvenile nasopharyngeal angiofibromas, and adrenal adenomas have also been associated with FAP. Congenital hypertrophy of the retinal pigment epithelium (CHRPE) is also a feature of the disease in some families [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/46\" class=\"abstract_t\">46</a>]. On slit lamp examination, CHRPE can be seen as discrete, darkly pigmented, round, oval, or kidney-shaped lesions. The presence of bilateral or multiple (more than four) lesions is specific (94 to 100 percent) but only moderately sensitive (58 to 84 percent) for FAP [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/47-49\" class=\"abstract_t\">47-49</a>]. CHRPE, as the name suggests, appears to be congenital and can be detected in children as young as three months. </p><p class=\"headingAnchor\" id=\"H534324085\"><span class=\"h2\">FAP variants</span></p><p class=\"headingAnchor\" id=\"H534324100\"><span class=\"h3\">Gardner syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gardner syndrome was a term used originally to describe families with colonic polyposis and extracolonic manifestations [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/50\" class=\"abstract_t\">50</a>]. These extraintestinal manifestations include desmoid tumors, sebaceous or epidermoid cysts, lipomas, osteomas (especially of the mandible), fibromas, supernumerary teeth, gastric fundic gland polyps, juvenile nasopharyngeal angiofibromas, and CHRPE. As Gardner syndrome is also caused by an underlying <em>APC</em> mutation, and most individuals with FAP invariably exhibit some extracolonic features, the distinction between FAP and Gardner syndrome is semantic, and the terms are essentially interchangeable [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/51\" class=\"abstract_t\">51</a>]. (See <a href=\"topic.htm?path=gardner-syndrome\" class=\"medical medical_review\">&quot;Gardner syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H625428197\"><span class=\"h3\">Turcot syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Turcot syndrome also known as brain tumor-polyposis syndrome is a historical term that originally described the association of familial colon cancer with brain tumors (primarily medulloblastomas and gliomas). [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/52\" class=\"abstract_t\">52</a>]. These terms have also been applied to patients with Lynch syndrome who develop brain tumors (astrocytoma or glioblastoma), despite the clear difference in the underlying genetics. [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/45\" class=\"abstract_t\">45</a>]. (See <a href=\"topic.htm?path=histopathology-and-molecular-pathogenesis-of-medulloblastoma#H4480314\" class=\"medical medical_review\">&quot;Histopathology and molecular pathogenesis of medulloblastoma&quot;, section on 'Turcot syndrome'</a> and <a href=\"topic.htm?path=lynch-syndrome-hereditary-nonpolyposis-colorectal-cancer-clinical-manifestations-and-diagnosis#H4\" class=\"medical medical_review\">&quot;Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis&quot;, section on 'Extracolonic manifestations'</a>.)</p><p class=\"headingAnchor\" id=\"H9689297\"><span class=\"h2\">Laboratory features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with FAP have no abnormal laboratory findings, but some patients may present with iron deficiency anemia due to unrecognized bleeding from adenomas [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H1251987977\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of familial adenomatous polyposis (FAP) should be suspected in any patient found to have 10 or more cumulative colorectal adenomas. It should also be suspected if an individual has a history of adenomas in combination with extracolonic features of FAP such as <span class=\"nowrap\">duodenal/ampullary</span> adenomas, desmoid tumors, papillary thyroid cancer, CHRPE, epidermal cysts, or osteomas, even if the absolute number of adenomas is lower.</p><p>In some circumstances, the clinical diagnosis of FAP is readily apparent by the autosomal dominant inheritance of diffuse colonic polyposis and classic extracolonic features. A germline mutation in the <em>APC</em> gene establishes a diagnosis of FAP [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/53-55\" class=\"abstract_t\">53-55</a>]. We perform genetic testing for FAP and <em>MUTYH</em>-associated polyposis (MAP) in individuals with 10 adenomas because of overlapping clinical features between FAP and MAP (<a href=\"image.htm?imageKey=GAST%2F65992\" class=\"graphic graphic_algorithm graphicRef65992 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/55-59\" class=\"abstract_t\">55-59</a>]. Broader multigene panel testing is now an option, and these panels typically include other polyposis associated genes (<em>DNA polymerase</em> &epsilon; [<em>POLE</em>] and &delta; [<em>POLD1</em>], and <em>Gremlin 1 homolog</em> [<em>GREM1</em>]).</p><p>Genetic counseling should be offered prior to genetic testing [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/60\" class=\"abstract_t\">60</a>]. A meticulous review of personal and family medical history, including verification of adenomatous histology is critical. (See <a href=\"topic.htm?path=genetic-testing\" class=\"medical medical_review\">&quot;Genetic testing&quot;</a> and <a href=\"topic.htm?path=familial-adenomatous-polyposis-screening-and-management-of-patients-and-families#H1790709413\" class=\"medical medical_review\">&quot;Familial adenomatous polyposis: Screening and management of patients and families&quot;, section on 'Colorectal cancer'</a>.)</p><p>If an <em>APC</em> mutation is identified, mutation-specific genetic testing should be offered to at-risk relatives of the index case. This includes all first-degree relatives of the index case and also first-degree relatives of those subsequently found to have an <em>APC</em> mutation. In addition, second-degree relatives can be offered genetic evaluation and testing when a family member declines genetic testing or has died. The reasonable age at which to begin genetic evaluation for <em>APC</em> mutation in minors is 10 to 12 years, prior to the initiation of screening colonoscopy. Earlier testing can be considered in families of patients with early onset tumors, including childhood hepatoblastoma [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/55\" class=\"abstract_t\">55</a>]. Prenatal genetic testing and preimplantation genetic diagnosis (PGD) specifically should be discussed as options in FAP patients of childbearing age [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/61\" class=\"abstract_t\">61</a>]. (See <a href=\"topic.htm?path=preimplantation-genetic-testing\" class=\"medical medical_review\">&quot;Preimplantation genetic testing&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1251987850\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with multiple colorectal polyps, it is essential to define the histology of the polyps. Multiple adenomatous polyps may also be found in cases with autosomal recessive <em>MUTYH</em>-associated polyposis (MAP) or Polymerase proofreading-associated polyposis (PPAP) that results from mutations in <em>DNA polymerase</em> &epsilon; (<em>POLE</em>) and &delta; (<em>POLD1</em>). Multiple colonic adenomas as well as duodenal adenomas and desmoid tumors were reported in the setting of <em>Gremlin 1 homolog</em> (<em>GREM1)</em>duplication [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/62\" class=\"abstract_t\">62</a>]. (See <a href=\"topic.htm?path=mutyh-associated-polyposis\" class=\"medical medical_review\">&quot;MUTYH-associated polyposis&quot;</a>.)</p><p>Individuals with attenuated familial adenomatous polyposis (AFAP) and who present with relatively few colorectal adenomas may be difficult to distinguish clinically from Lynch syndrome or sporadic adenomas. Only genetic testing can definitively distinguish between familial adenomatous polyposis (FAP), MAP, and Lynch syndrome, although an autosomal dominant pattern of colorectal cancer in a family would make MAP unlikely. (See <a href=\"#H547090028\" class=\"local\">'Genetics'</a> above and <a href=\"topic.htm?path=lynch-syndrome-hereditary-nonpolyposis-colorectal-cancer-clinical-manifestations-and-diagnosis#H345552210\" class=\"medical medical_review\">&quot;Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis&quot;, section on 'Genetics'</a>.)</p><p>A significant number of individuals with multiple colorectal adenomas have no mutation in the <em>APC</em> or <em>MUTYH </em>genes [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/63\" class=\"abstract_t\">63</a>]. Rare families with polyposis due to germline mutations in <em>POLE</em>, <em>POLD1</em>, and <em>GREM1</em> have been described [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/1\" class=\"abstract_t\">1</a>], and there may well be other, as yet unidentified, polyposis genes. A cross-sectional study examined the prevalence of <em>APC</em> and <em>MUTYH</em> mutations in 8676 individuals with a personal or family history suggestive of a polyposis syndrome who underwent clinical genetic testing [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/63\" class=\"abstract_t\">63</a>]. The prevalence of <em>APC</em> and <em>MUTYH </em>mutations was 80 and 2 percent, respectively, among individuals with &gt;1000 adenomas (classic polyposis), 56 and 8 percent, respectively, among individuals with 100 to 999 adenomas (classic polyposis), 10 and 7 percent, respectively, among individuals with 20 to 99 adenomas (attenuated polyposis), and 5 and 4 percent, respectively, among individuals with 10 to 19 adenomas. In this study, 34 percent of individuals with extensive polyposis (&gt;100 adenomas) and 81 percent of individuals with an attenuated polyposis phenotype (20 to 99 adenomas) had no mutation in either the <em>APC</em> or <em>MUTYH</em> gene.</p><p class=\"headingAnchor\" id=\"H1814135750\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-hereditary-colorectal-cancer-syndromes\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Hereditary colorectal cancer syndromes&quot;</a>.) </p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=familial-adenomatous-polyposis-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Familial adenomatous polyposis (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H11752552\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome caused by germline mutations in the adenomatous polyposis coli (<em>APC</em>) gene on chromosome 5q21-q22. (See <a href=\"#H547090028\" class=\"local\">'Genetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>FAP occurs in approximately <span class=\"nowrap\">1/10,000</span> to <span class=\"nowrap\">1/30,000</span> live births, and accounts for less than 1 percent of all colorectal cancers in the United States. (See <a href=\"#H11752503\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>FAP is characterized by the presence of multiple colorectal adenomas. In classic FAP, there are &gt;100 adenomatous colorectal polyps. Polyposis typically develops in the second or third decade of life and colorectal cancer occurs in essentially 100 percent of untreated individuals. <br/><br/>Attenuated FAP (AFAP) is characterized by more than 10 to 20 adenomas but fewer than 100. Individuals with AFAP have up to an 80 percent risk of developing colorectal cancer at an average age of 56 years. (See <a href=\"#H534324675\" class=\"local\">'Colonic manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fundic gland polyps are found in most patients with FAP but rarely progress to cancer. Duodenal adenomas occur in 45 to 90 percent of patients with FAP, most commonly at or adjacent to the ampulla. Patients with FAP have a 5 percent lifetime risk of duodenal cancer. Individuals with FAP are also at risk for follicular or papillary thyroid cancer, childhood hepatoblastoma, and central nervous system tumors, but these are much less common than colon and duodenal cancer. (See <a href=\"#H534324165\" class=\"local\">'Extracolonic manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of FAP should be suspected in individuals with &gt;10 cumulative colorectal adenomas or a history of adenomas in combination with extracolonic features associated with FAP (eg, <span class=\"nowrap\">duodenal/ampullary</span> adenomas, desmoid tumors, papillary thyroid cancer, congenital hypertrophy of the retinal pigment epithelium, epidermal cysts, or osteomas). Germline mutations in the <em>APC </em>gene establish the diagnosis of FAP or attenuated FAP. (See <a href=\"#H1251987977\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H4116153877\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The UpToDate editorial staff would like to thank Drs. Dennis J. Ahnen and Lisen Axell for their contributions as authors to prior versions of this topic review. </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/1\" class=\"nounderline abstract_t\">Vasen HF, Tomlinson I, Castells A. Clinical management of hereditary colorectal cancer syndromes. Nat Rev Gastroenterol Hepatol 2015; 12:88.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/2\" class=\"nounderline abstract_t\">Wennstrom J, Pierce ER, McKusick VA. Hereditary benign and malignant lesions of the large bowel. Cancer 1974; 34:suppl:850.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/3\" class=\"nounderline abstract_t\">J&auml;rvinen HJ. Epidemiology of familial adenomatous polyposis in Finland: impact of family screening on the colorectal cancer rate and survival. Gut 1992; 33:357.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/4\" class=\"nounderline abstract_t\">Burt RW, DiSario JA, Cannon-Albright L. Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med 1995; 46:371.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/5\" class=\"nounderline abstract_t\">Bisgaard ML, Fenger K, B&uuml;low S, et al. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 1994; 3:121.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/6\" class=\"nounderline abstract_t\">Laurent-Puig P, B&eacute;roud C, Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 1998; 26:269.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/7\" class=\"nounderline abstract_t\">Moisio AL, J&auml;rvinen H, Peltom&auml;ki P. Genetic and clinical characterisation of familial adenomatous polyposis: a population based study. Gut 2002; 50:845.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/8\" class=\"nounderline abstract_t\">Michils G, Tejpar S, Thoelen R, et al. Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study. Hum Mutat 2005; 25:125.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/9\" class=\"nounderline abstract_t\">Aretz S, Stienen D, Uhlhaas S, et al. Large submicroscopic genomic APC deletions are a common cause of typical familial adenomatous polyposis. J Med Genet 2005; 42:185.</a></li><li class=\"breakAll\">Leiden Open Variation Database. InSiGHT (International Society for Gastrointestinal Hereditary Tumours), Leiden University Medical Center. Available at: http://chromium.liacs.nl/LOVD2/colon_cancer/ (Accessed on January 17, 2012).</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/11\" class=\"nounderline abstract_t\">Lamlum H, Papadopoulou A, Ilyas M, et al. APC mutations are sufficient for the growth of early colorectal adenomas. Proc Natl Acad Sci U S A 2000; 97:2225.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/12\" class=\"nounderline abstract_t\">Lamlum H, Ilyas M, Rowan A, et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med 1999; 5:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/13\" class=\"nounderline abstract_t\">Giardiello FM, Krush AJ, Petersen GM, et al. Phenotypic variability of familial adenomatous polyposis in 11 unrelated families with identical APC gene mutation. Gastroenterology 1994; 106:1542.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/14\" class=\"nounderline abstract_t\">Heinen CD. Genotype to phenotype: analyzing the effects of inherited mutations in colorectal cancer families. Mutat Res 2010; 693:32.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/15\" class=\"nounderline abstract_t\">J&auml;rvinen HJ, Peltom&auml;ki P. The complex genotype-phenotype relationship in familial adenomatous polyposis. Eur J Gastroenterol Hepatol 2004; 16:5.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/16\" class=\"nounderline abstract_t\">Giardiello FM, Petersen GM, Piantadosi S, et al. APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis. Gut 1997; 40:521.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/17\" class=\"nounderline abstract_t\">Olschwang S, Tiret A, Laurent-Puig P, et al. Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. Cell 1993; 75:959.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/18\" class=\"nounderline abstract_t\">Caspari R, Olschwang S, Friedl W, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 1995; 4:337.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/19\" class=\"nounderline abstract_t\">Soravia C, Berk T, Madlensky L, et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998; 62:1290.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/20\" class=\"nounderline abstract_t\">Davies DR, Armstrong JG, Thakker N, et al. Severe Gardner syndrome in families with mutations restricted to a specific region of the APC gene. Am J Hum Genet 1995; 57:1151.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/21\" class=\"nounderline abstract_t\">Saurin JC, Ligneau B, Ponchon T, et al. The influence of mutation site and age on the severity of duodenal polyposis in patients with familial adenomatous polyposis. Gastrointest Endosc 2002; 55:342.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/22\" class=\"nounderline abstract_t\">Attard TM, Giglio P, Koppula S, et al. Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer 2007; 109:761.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/23\" class=\"nounderline abstract_t\">Croner RS, Brueckl WM, Reingruber B, et al. Age and manifestation related symptoms in familial adenomatous polyposis. BMC Cancer 2005; 5:24.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/24\" class=\"nounderline abstract_t\">Leoz ML, Carballal S, Moreira L, et al. The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. Appl Clin Genet 2015; 8:95.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/25\" class=\"nounderline abstract_t\">Petersen GM, Slack J, Nakamura Y. Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 1991; 100:1658.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/26\" class=\"nounderline abstract_t\">Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110:223.</a></li><li class=\"breakAll\">Bussey et al Bussey HJR. Familial Polyposis Coli. Family Studies, Histopathology, Differential Diagnosis and Results of Treatment, Johns Hopkins UniversityPress, Baltimore 1975.</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/28\" class=\"nounderline abstract_t\">Spirio L, Olschwang S, Groden J, et al. Alleles of the APC gene: an attenuated form of familial polyposis. Cell 1993; 75:951.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/29\" class=\"nounderline abstract_t\">Brensinger JD, Laken SJ, Luce MC, et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3' mutation in the APC gene. Gut 1998; 43:548.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/30\" class=\"nounderline abstract_t\">Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 1995; 76:2427.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/31\" class=\"nounderline abstract_t\">Burt RW, Leppert MF, Slattery ML, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology 2004; 127:444.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/32\" class=\"nounderline abstract_t\">Sieber OM, Segditsas S, Knudsen AL, et al. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation. Gut 2006; 55:1440.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/33\" class=\"nounderline abstract_t\">Hernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. Dis Colon Rectum 2002; 45:127.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/34\" class=\"nounderline abstract_t\">Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet 1988; 1:1149.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/35\" class=\"nounderline abstract_t\">Wallace MH, Phillips RK. Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br J Surg 1998; 85:742.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/36\" class=\"nounderline abstract_t\">Burt RW. Gastric fundic gland polyps. Gastroenterology 2003; 125:1462.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/37\" class=\"nounderline abstract_t\">Bianchi LK, Burke CA, Bennett AE, et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6:180.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/38\" class=\"nounderline abstract_t\">Hamilton SR, Bussey HJ, Mendelsohn G, et al. Ileal adenomas after colectomy in nine patients with adenomatous polyposis coli/Gardner's syndrome. Gastroenterology 1979; 77:1252.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/39\" class=\"nounderline abstract_t\">Parc YR, Olschwang S, Desaint B, et al. Familial adenomatous polyposis: prevalence of adenomas in the ileal pouch after restorative proctocolectomy. Ann Surg 2001; 233:360.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/40\" class=\"nounderline abstract_t\">Primrose JN, Quirke P, Johnston D. Carcinoma of the ileostomy in a patient with familial adenomatous polyposis. Br J Surg 1988; 75:384.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/41\" class=\"nounderline abstract_t\">Slowik V, Attard T, Dai H, et al. Desmoid tumors complicating Familial Adenomatous Polyposis: a meta-analysis mutation spectrum of affected individuals. BMC Gastroenterol 2015; 15:84.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/42\" class=\"nounderline abstract_t\">Jarrar AM, Milas M, Mitchell J, et al. Screening for thyroid cancer in patients with familial adenomatous polyposis. Ann Surg 2011; 253:515.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/43\" class=\"nounderline abstract_t\">Feng X, Milas M, O'Malley M, et al. Characteristics of benign and malignant thyroid disease in familial adenomatous polyposis patients and recommendations for disease surveillance. Thyroid 2015; 25:325.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/44\" class=\"nounderline abstract_t\">Tomoda C, Miyauchi A, Uruno T, et al. Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 2004; 28:886.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/45\" class=\"nounderline abstract_t\">Groen EJ, Roos A, Muntinghe FL, et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 2008; 15:2439.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/46\" class=\"nounderline abstract_t\">Touri&ntilde;o R, Conde-Freire R, Cabezas-Agr&iacute;cola JM, et al. Value of the congenital hypertrophy of the retinal pigment epithelium in the diagnosis of familial adenomatous polyposis. Int Ophthalmol 2004; 25:101.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/47\" class=\"nounderline abstract_t\">Wallis YL, Macdonald F, Hult&eacute;n M, et al. Genotype-phenotype correlation between position of constitutional APC gene mutation and CHRPE expression in familial adenomatous polyposis. Hum Genet 1994; 94:543.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/48\" class=\"nounderline abstract_t\">Bertario L, Bandello F, Rossetti C, et al. Congenital hypertrophy of retinal pigment epithelium (CHRPE) as a marker for familial adenomatous polyposis (FAP). Eur J Cancer Prev 1993; 2:69.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/49\" class=\"nounderline abstract_t\">Tiret A, Taiel-Sartral M, Tiret E, Laroche L. Diagnostic value of fundus examination in familial adenomatous polyposis. Br J Ophthalmol 1997; 81:755.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/50\" class=\"nounderline abstract_t\">GARDNER EJ, RICHARDS RC. Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am J Hum Genet 1953; 5:139.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/51\" class=\"nounderline abstract_t\">Bisgaard ML, B&uuml;low S. Familial adenomatous polyposis (FAP): genotype correlation to FAP phenotype with osteomas and sebaceous cysts. Am J Med Genet A 2006; 140:200.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/52\" class=\"nounderline abstract_t\">TURCOT J, DESPRES JP, ST PIERRE F. Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum 1959; 2:465.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/53\" class=\"nounderline abstract_t\">NCCN colorectal cancer screening practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park) 1999; 13:152.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/54\" class=\"nounderline abstract_t\">Burt R, Neklason DW. Genetic testing for inherited colon cancer. Gastroenterology 2005; 128:1696.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/55\" class=\"nounderline abstract_t\">American Gastroenterological Association. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121:195.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/56\" class=\"nounderline abstract_t\">Vasen HF, M&ouml;slein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57:704.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/57\" class=\"nounderline abstract_t\">Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121:198.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/58\" class=\"nounderline abstract_t\">Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009; 104:739.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/59\" class=\"nounderline abstract_t\">Burt RW, Barthel JS, Dunn KB, et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2010; 8:8.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/60\" class=\"nounderline abstract_t\">Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28:893.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/61\" class=\"nounderline abstract_t\">Kastrinos F, Stoffel EM, Balma&ntilde;a J, Syngal S. Attitudes toward prenatal genetic testing in patients with familial adenomatous polyposis. Am J Gastroenterol 2007; 102:1284.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/62\" class=\"nounderline abstract_t\">Church JM. Polymerase proofreading-associated polyposis: a new, dominantly inherited syndrome of hereditary colorectal cancer predisposition. Dis Colon Rectum 2014; 57:396.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis/abstract/63\" class=\"nounderline abstract_t\">Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 2012; 308:485.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2593 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H11752552\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H11752496\" id=\"outline-link-H11752496\">INTRODUCTION</a></li><li><a href=\"#H11752503\" id=\"outline-link-H11752503\">EPIDEMIOLOGY</a></li><li><a href=\"#H547090028\" id=\"outline-link-H547090028\">GENETICS</a></li><li><a href=\"#H11752517\" id=\"outline-link-H11752517\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H534324675\" id=\"outline-link-H534324675\">Colonic manifestations</a><ul><li><a href=\"#H534324030\" id=\"outline-link-H534324030\">- Classic FAP</a></li><li><a href=\"#H103627351\" id=\"outline-link-H103627351\">- Attenuated FAP</a></li></ul></li><li><a href=\"#H534324165\" id=\"outline-link-H534324165\">Extracolonic manifestations</a></li><li><a href=\"#H534324085\" id=\"outline-link-H534324085\">FAP variants</a><ul><li><a href=\"#H534324100\" id=\"outline-link-H534324100\">- Gardner syndrome</a></li><li><a href=\"#H625428197\" id=\"outline-link-H625428197\">- Turcot syndrome</a></li></ul></li><li><a href=\"#H9689297\" id=\"outline-link-H9689297\">Laboratory features</a></li></ul></li><li><a href=\"#H1251987977\" id=\"outline-link-H1251987977\">DIAGNOSIS</a></li><li><a href=\"#H1251987850\" id=\"outline-link-H1251987850\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H1814135750\" id=\"outline-link-H1814135750\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H10463639\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H11752552\" id=\"outline-link-H11752552\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H4116153877\" id=\"outline-link-H4116153877\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/2593|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=GAST/65992\" class=\"graphic graphic_algorithm\">- FAP gene testing algorithm</a></li></ul></li><li><div id=\"GAST/2593|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/58291\" class=\"graphic graphic_figure\">- CRC in genetic syndromes</a></li></ul></li><li><div id=\"GAST/2593|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/59413\" class=\"graphic graphic_picture\">- Familial polyposis Endosc</a></li><li><a href=\"image.htm?imageKey=GAST/73267\" class=\"graphic graphic_picture\">- Familial polyposis Gross</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-diagnosis-and-risk-stratification-of-medulloblastoma\" class=\"medical medical_review\">Clinical presentation, diagnosis, and risk stratification of medulloblastoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-diagnosis-and-staging-of-colorectal-cancer\" class=\"medical medical_review\">Clinical presentation, diagnosis, and staging of colorectal cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=familial-adenomatous-polyposis-screening-and-management-of-patients-and-families\" class=\"medical medical_review\">Familial adenomatous polyposis: Screening and management of patients and families</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gardner-syndrome\" class=\"medical medical_review\">Gardner syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gastric-polyps\" class=\"medical medical_review\">Gastric polyps</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetic-testing\" class=\"medical medical_review\">Genetic testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetics-glossary-of-terms\" class=\"medical medical_review\">Genetics: Glossary of terms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=histopathology-and-molecular-pathogenesis-of-medulloblastoma\" class=\"medical medical_review\">Histopathology and molecular pathogenesis of medulloblastoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=inheritance-patterns-of-monogenic-disorders-mendelian-and-non-mendelian\" class=\"medical medical_review\">Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=juvenile-polyposis-syndrome\" class=\"medical medical_review\">Juvenile polyposis syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lynch-syndrome-hereditary-nonpolyposis-colorectal-cancer-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mutyh-associated-polyposis\" class=\"medical medical_review\">MUTYH-associated polyposis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=molecular-genetics-of-colorectal-cancer\" class=\"medical medical_review\">Molecular genetics of colorectal cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome\" class=\"medical medical_review\">PTEN hamartoma tumor syndrome, including Cowden syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=papillary-thyroid-cancer\" class=\"medical medical_review\">Papillary thyroid cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=familial-adenomatous-polyposis-the-basics\" class=\"medical medical_basics\">Patient education: Familial adenomatous polyposis (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=preimplantation-genetic-testing\" class=\"medical medical_review\">Preimplantation genetic testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-hereditary-colorectal-cancer-syndromes\" class=\"medical medical_society_guidelines\">Society guideline links: Hereditary colorectal cancer syndromes</a></li></ul></div></div>","javascript":null}